← FDA DRUG APPROVALS

FDA ANDA · ANDA083232

HYDROCHLOROTHIAZIDE

Sponsor: WATSON LABS TEVA

APPLICATION
ANDA083232
TYPE
ANDA
ORIGINAL APPROVAL
1975-01-24
LATEST ACTION
1995-12-13
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Discontinued

Products

HYDROCHLOROTHIAZIDEDiscontinued
HYDROCHLOROTHIAZIDE 50MG · TABLET · ORAL

Approval history

1995-12-13Labeling · Supplement 57AP
1995-09-12Labeling · Supplement 56AP
1993-08-03Labeling · Supplement 55AP
1992-10-06Labeling · Supplement 54AP
1990-11-19Manufacturing (CMC) · Supplement 53AP
1990-06-29Manufacturing (CMC) · Supplement 50AP
1989-07-12Labeling · Supplement 51AP
1989-05-04Labeling · Supplement 49AP
1988-09-20Manufacturing (CMC) · Supplement 46AP
1988-09-20Labeling · Supplement 47AP
1988-09-20Manufacturing (CMC) · Supplement 45AP
1988-02-19Manufacturing (CMC) · Supplement 42AP
1988-02-19Manufacturing (CMC) · Supplement 43AP
1987-12-16Manufacturing (CMC) · Supplement 40AP
1987-12-16Manufacturing (CMC) · Supplement 39AP
1987-12-16Manufacturing (CMC) · Supplement 41AP
1985-06-03Manufacturing (CMC) · Supplement 34AP
1985-06-03Manufacturing (CMC) · Supplement 33AP
1985-01-22Manufacturing (CMC) · Supplement 32AP
1984-01-13Manufacturing (CMC) · Supplement 31AP
1983-05-23Manufacturing (CMC) · Supplement 28AP
1983-05-23Manufacturing (CMC) · Supplement 29AP
1982-08-16Manufacturing (CMC) · Supplement 26AP
1975-01-24Original — Review ↗AP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industry →GMP discipline →FDA drug shortages →FDA enforcement & recalls →

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →